Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00677014 · ClinicalTrials.gov registry record · Phase 4
Comparison of AV Optimization Methods Used in Cardiac Resynchronization Therapy (CRT)
A Phase 4 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,060
- Enrollment target
NCT00677014 is a Phase 4 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 1,060 participants.
The verdict
NCT00677014, a Phase 4 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,060 participants
- Enrollment target
Study Summary
The primary objective of SMART-AV is to assess the effect of SmartDelay for determining optimal AV delay timing during CRT compared to both a fixed AV delay and echocardiography-determined optimal AV timing chronically over a 6-month period.
Interventions
- DEVICE AV Delay programming through cardiac resynchronization therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,060 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00677014
The ClinicalTrials.gov registry entry for NCT00677014 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,060 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AV Delay programming through cardiac resynchronization therapy is the first listed.
NCT00677014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00677014 about?
NCT00677014 is a clinical study titled "Comparison of AV Optimization Methods Used in Cardiac Resynchronization Therapy (CRT)". The primary objective of SMART-AV is to assess the effect of SmartDelay for determining optimal AV delay timing during CRT compared to both a fixed AV delay and echocardiography-determined optimal AV timing chronically over a 6-month period.
What is the current status of trial NCT00677014?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,060 participants. The study started on 2008-05. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00677014?
The interventions under investigation include: AV Delay programming through cardiac resynchronization therapy (DEVICE).
Who is sponsoring clinical trial NCT00677014?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.